Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron ...

The February 2025 acquisition of Ambry Genetics further expands TEM's genomics capabilities with a West Coast lab and ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading ... including our ability to realize the expected benefits of the acquisition of Ambry Genetics; the potential adverse impact of climate ...

Tempus AI, a health tech firm, offers AI-powered platforms for treatment decisions, patient care, diagnostics, and molecular profiling, with growing revenue and improving margins. The "AI in ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark broader industry growth?

Tempus AI started off the year with a stellar ... a 79% YoY growth, bolstered by the Ambry Genetics acquisition and a rapidly growing TAM. Despite the deep selloff recently, I rank TEM a 'Strong ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

For the full year, the Data and Services division was a key contributor. The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a ...

Tempus AI's acquisition of Ambry Genetics, finalized on February 3, 2025, for $375 million in cash and $225 million in stock, has significantly boosted investor confidence. This strategic move ...